Malignancy risk factors and prognostic variables of pancreatic mucinous cystic neoplasms in Chinese patients

Table 1 Clinicopathologic and radiological features in 48 patients

Variable	Benign group (n = 36)	Malignant group (n = 12)	P value
Sex			0.142
Male	8 (22.2)	6 (50.0)
Female	28 (77.8)	6 (50.0)
Age, yr			0.013
≥ 50	8 (22.2)	8 (66.7)
< 50	28 (77.8)	4 (33.3)
Clinical symptoms			0.499
Yes	20 (55.6)	8 (66.7)
No	16 (44.4)	4 (33.3)
Serum CA19-9 level			0.077
Elevate	9 (25)	7 (58.3)
Normal	27 (75)	5 (41.7)
Tumor size, cm			0.005
≥ 4	13 (36.1)	10 (83.3)
< 4	23 (63.9)	2 (16.7)
Location			0.348
Head and neck	8 (22.2)	5 (41.7)
Body and tail	28 (77.8)	7 (58.3)
Duct dilatation			0.039
Yes	10 (27.8)	8 (66.7)
No	26 (72.2)	4 (33.3)
Solid component/mural nodule			0.039
Yes	10 (27.8)	8 (66.7)
No	26 (72.2)	4 (33.3)
Septations			0.867
Yes	16 (44.4)	5 (41.7)
No	20 (55.6)	7 (58.3)
Calcification			0.851
Yes	9 (25)	4 (33.3)
No	27 (75)	8 (66.7)

Significant P in bold. Data presented in parentheses represent percentages. CA19-9: Carbohydrate antigen 19-9.

Table 2 Characteristics of 11 patients with mucinous cystic neoplasm‐associated invasive carcinoma

Case	Age (yr)	Sex	Tumor size (cm)	Largest dimension (cm)	Invasion pattern	pT stage	pTNM stage	Status	Overall survival (mo)	Adjuvant chemotherapy
1	72	Female	8.0	3.0	Extracapsular	T2	IB	Death	8	Yes
2	60	Male	14.0	1.2	Extracapsular	T1	IA	Death	14	Yes
3	57	Male	7.2	4.0	Extracapsular	T2	IB	Death	46	No
4	64	Female	5.0	< 0.1	Encapsulated	T1	IA	Alive	56	Yes
5	56	Male	6.4	2.0	Encapsulated	T1	IA	Alive	53	Yes
6	43	Female	5.0	< 0.1	Encapsulated	T1	IA	Alive	38	No
7	52	Female	4.5	3.0	Encapsulated	T2	IB	Alive	47	No
8	28	Male	11.0	2.0	Encapsulated	T1	IA	Alive	104	Yes
9	34	Female	3.0	< 0.2	Encapsulated	T1	IA	Alive	75	No
10	45	Male	4.0	1.5	Encapsulated	T1	IA	Alive	24	No
11	63	Female	6.0	< 0.2	Encapsulated	T1	IA	Alive	94	Yes